Switzerland· 66879001
Mylotarg 5 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
A gemtuzumab ozogamicin product containing gemtuzumabum ozogamicinum, registered in Switzerland by Pfizer AG and dispensed under Swissmedic category A. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Gemtuzumab ozogamicin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX02 (gemtuzumab ozogamicin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Gemtuzumab ozogamicin · ATC L01FX02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- gemtuzumabum ozogamicinum
- Manufacturer
- Pfizer AG
- Country
- Switzerland (CH)
- ATC code
- L01FX02
- ATC class
- Gemtuzumab ozogamicin
- Defined daily dose
- 2.1 mg, P
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
112 interactions on record for gemtuzumab ozogamicin.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gemtuzumab ozogamicin · interactions on record
112 records
- 33 severe
- 64 moderate
- 15 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gemtuzumab ozogamicin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumMylotarg 5 mgPfizer Europe MA
- CzechiaMYLOTARGPfizer Europe MA EEIG, Bruxelles
- SpainMYLOTARG 5 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Europe Ma Eeig
- FinlandMYLOTARGPfizer Europe MA EEIG
- United KingdomMylotarg 5mg powder for concentrate for solution for infusion vialsPfizer Ltd
- IrelandMYLOTARG 5 mg powder for concentrate for solution for infusionPfizer Europe MA EEIG
- IcelandMylotargPfizer Europe MA EEIG*
- NorwayMylotargPfizer Europe MA EEIG (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mylotarg
- Liechtenstein · Mylotarg
- Norway · Mylotarg
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1332a7eb-7819-4517-9ddb-8ee4d712034c GET /v1/drugs/1332a7eb-7819-4517-9ddb-8ee4d712034c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about gemtuzumab ozogamicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.